References
- Warner M, Trinidad JP, Bastian BA, et al. Drugs most frequently involved in drug overdose deaths: United States, 2010–2014. Natl Vital Stat Rep. 2016;65(10):1–15.
- Drug Scheduling. [cited 2020 May 11]. Available from: https://www.dea.gov/drug-scheduling
- DEA To Publish Final Rule Rescheduling Hydrocodone Combination Products. [cited 2020 May 11]. Available from: https://www.dea.gov/press-releases/2014/08/21/dea-publish-final-rule-rescheduling-hydrocodone-combination-products
- Tran S, Lavitas P, Stevens K, et al. The effect of a federal controlled substance act schedule change on hydrocodone combination products claims in a medicaid population. JMCP. 2017;23(5):532–539.
- DEA Final Rule Rescheduling Hydrocodone Combination Products; 2014. Available from: https://www.asahq.org/-/media/sites/asahq/files/public/advocacy/federal-activities/regulatory-activities/pain-medicine/rescheduling-hydrocodone-products.pdf.
- Seago S, Hayek A, Pruszynski J, et al. Change in prescription habits after federal rescheduling of hydrocodone combination products. Proc (Bayl Univ Med Cent). 2016;29(3):268–270.
- Shumway JW, Ran R, McClusky J, et al. Impact of rescheduling hydrocodone-combination products in an urban Texas county healthcare system. J Opioid Manag. 2018;14(4):257–264.
- Liu Y, Baker O, Schuur JD, et al. Effects of rescheduling hydrocodone on opioid prescribing in Ohio. Pain Med. 2019. DOI:10.1093/pm/pnz210
- Kuschel LM, Mort JM. Impact of the hydrocodone schedule change on opioid prescription patterns in South Dakota. S D Med. 2017;70(10):449–455.
- Raji MA, Kuo Y-F, Adhikari D, et al. Decline in opioid prescribing after federal rescheduling of hydrocodone products. Pharmacoepidemiol Drug Saf. 2018;27(5):513–519.
- Harrison ML, Walsh TL. The effect of a more strict 2014 DEA schedule designation for hydrocodone products on opioid prescription rates in the United States. Clin Toxicol (Phila). 2019;57(11):1064–1072.
- Haynes A, Kleinschmidt K, Forrester MB, et al. Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone. Clin Toxicol (Phila). 2016;54(5):434–440.
- Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the United States: an update. Am J Psychiatry. 2016;173(1):18–26.
- American Association of Poison Control Centers (AAPCC) - Notes About Poison Control Data. [cited 2020 May 11]. Available from: https://aapcc.org/datainfo
- Critical appraisal of extended-release hydrocodone for chronic pain: patient considerations. [cited 2020 May 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622415/
- Choy M. Pharmaceutical approval update. Pharm Ther. 2017;42(4):235–255. [cited 2020 May 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358679/
- American Association of Poison Control Centers. 2019. National Poison Data System (NDPS) Coding User’s Manual Version 4.1 (April 16). Available from: https://bezoar.georgiapoisoncenter.org/wp-content/uploads/2014/07/NPDS-2019.pdf
- Linden A. Conducting interrupted time-series analysis for single- and multiple-group comparisons. Stata J. 2015;15(2):480–500.
- Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34(5):502–508.
- Martin J, Cunliffe J, Décary-Hétu D, et al. Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis. BMJ. 2018;361:k2270.
- Beletsky L, Davis CS. Today’s fentanyl crisis: Prohibition’s Iron Law, revisited. Int J Drug Policy. 2017;46:156–159.
- California’s Activities. [cited 2020 May 11]. Available from: https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/SACB/Pages/CaliforniasStrategiesAndActivities.aspx
- National Institute on Drug Abuse. Overdose Death Rates. [Published 2020 Mar 10; cited 2020 May 11]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates